Baili Tianheng (688506.SH): 2023 net profit - 780 million yuan

Gelonghui, April 26丨Baili Tianheng (688506.SH) released its 2023 annual report. During the reporting period, the company achieved operating revenue of 562 million yuan, a decrease of 20.11% over the same period last year. Net profit attributable to listed companies - $780 million, a decrease of 176.40% compared with the same period last year. The main reason was that phase III clinical trials continued to be invested in pre-clinical research and clinical trial research during the reporting period. As R&D progress continued to advance, R&D investment increased, leading to a continuous increase in the company's R&D expenses.

Gelonghui FinanceApr 26 11:23 ET

Sichuan Biokin Pharmaceutical Gets Approval to Trial Lung Cancer Drug

Sichuan Biokin Pharmaceutical (SHA:688506) will conduct clinical trials on BL-B01D1 for injection after receiving approval from China's National Medical Products Administration, according to the compa

MT NewswiresApr 22 00:37 ET

Baili Tianheng (688506.SH): “BL-B01D1+PD-1 monoclonal antibody ± chemotherapy” for locally advanced or metastatic non-small cell lung cancer obtained approval notice for phase II clinical trials

Gelonghui, April 21丨Baili Tianheng (688506.SH) announced that the combination drug “BL-B01D1+PD-1 monoclonal antibody ± chemotherapy” related to the innovative biopharmaceutical injectable BL-B01D1 (EGFR×HER3-ADC) independently developed by the company recently received the “Drug Clinical Trial Approval Notice” officially approved and issued by the National Drug Administration (NMPA). BL-B01D1 is a globally exclusive clinical-stage dual-antibody ADC drug independently developed by the company that targets both EGFR and HER3. EGFR and/or HER3 are in most epithelium

Gelonghui FinanceApr 21 04:25 ET

Chinese Drug Regulator Puts Sichuan Biokin Pharmaceutical's Naxopharynx Cancer Drug in Breakthrough Drugs List

China's National Medical Products Administration included Sichuan Biokin Pharmaceutical's (SHA:688506) BL-B01D1 for injection in the list of breakthrough therapy drugs, according to the company's disc

MT NewswiresApr 18 02:55 ET

Baili Tianheng (688506.SH): Injectable BL-B01D1 is used to treat terminal patients with locally advanced or metastatic nasopharyngeal cancer included in the list of breakthrough treatment varieties

Baili Tianheng (688506.SH) announced that the company's self-developed innovative biopharmaceutical injectable BL-B01D1...

Zhitong FinanceApr 17 03:55 ET

Baili Tianheng (688506.SH): BL-B01D1 for injection completed the first case of recurrent or metastatic esophageal squamous cell carcinoma phase III clinical trial

Gelonghui, April 9 | Bailey Tianheng (688506.SH) announced that the self-developed innovative biopharmaceutical injectable BL-B01D1 (EGFR×HER3-ADC) is currently undergoing phase III clinical trials for recurrent or metastatic esophageal squamous cell carcinoma, and has recently successfully completed the first case of the subject.

Gelonghui FinanceApr 9 05:26 ET